Sign in or create an account to add this stock to your watchlist.
About Cellectis (NASDAQ:CLLS)
Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00
Debt
Debt-to-Equity RatioN/A
Current Ratio7.18
Quick Ratio7.17
Price-To-Earnings
Trailing P/E Ratio-10.93
Forward P/E Ratio-11.38
P/E GrowthN/A
Sales & Book Value
Annual Sales$33.72 million
Price / Sales37.49
Cash FlowN/A
Price / CashN/A
Book Value$6.65 per share
Price / Book4.57
Profitability
EPS (Most Recent Fiscal Year)($2.78)
Net Income$-99,360,000.00
Net Margins-337.45%
Return on Equity-37.45%
Return on Assets-31.83%
Miscellaneous
Employees122
Outstanding Shares41,600,000
Cellectis (NASDAQ:CLLS) Frequently Asked Questions
What is Cellectis' stock symbol?
Cellectis trades on the NASDAQ under the ticker symbol "CLLS."
How were Cellectis' earnings last quarter?
Cellectis (NASDAQ:CLLS) posted its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing the Zacks' consensus estimate of ($0.70) by $0.01. The biotechnology company earned $8.07 million during the quarter, compared to analysts' expectations of $9.53 million. Cellectis had a negative net margin of 337.45% and a negative return on equity of 37.45%. View Cellectis' Earnings History.
When is Cellectis' next earnings date?
What price target have analysts set for CLLS?
6 brokers have issued 1 year price targets for Cellectis' shares. Their predictions range from $20.00 to $73.00. On average, they expect Cellectis' share price to reach $44.00 in the next twelve months. View Analyst Ratings for Cellectis.
Who are some of Cellectis' key competitors?
Some companies that are related to Cellectis include arGEN-X BV (ARGX), CRISPR Therapeutics (CRSP), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX) and Iovance Biotherapeutics (IOVA).
Who are Cellectis' key executives?
Cellectis' management team includes the folowing people:
- Dr. André Choulika Ph.D., Co-Founder, Chairman and Chief Exec. Officer (Age 53)
- Dr. David J. D. Sourdive Ph.D., Co-Founder, Exec. VP - Technical Operations and Director (Age 51)
- Mr. Eric Dutang, Chief Financial Officer (Age 44)
- Ms. Elsy Boglioli, Chief Operating Officer
- Dr. Philippe Duchateau Ph.D., Chief Scientific Officer (Age 55)
When did Cellectis IPO?
(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.
Has Cellectis been receiving favorable news coverage?
Media coverage about CLLS stock has trended positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cellectis earned a news sentiment score of 0.29 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.04 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Cellectis' major shareholders?
Cellectis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Nexthera Capital LP (0.80%), BlackRock Inc. (0.30%), Point72 Asset Management L.P. (0.17%), JPMorgan Chase & Co. (0.16%), Bellevue Group AG (0.13%) and Jane Street Group LLC (0.12%). View Institutional Ownership Trends for Cellectis.
Which major investors are selling Cellectis stock?
Which major investors are buying Cellectis stock?
CLLS stock was purchased by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Point72 Asset Management L.P., Jane Street Group LLC, JPMorgan Chase & Co., Bellevue Group AG, A.R.T. Advisors LLC, Wells Fargo & Company MN and Trellus Management Company LLC. View Insider Buying and Selling for Cellectis.
How do I buy shares of Cellectis?
Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellectis' stock price today?
One share of CLLS stock can currently be purchased for approximately $30.39.
How big of a company is Cellectis?
Cellectis has a market capitalization of $1.27 billion and generates $33.72 million in revenue each year. The biotechnology company earns $-99,360,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Cellectis employs 122 workers across the globe.
How can I contact Cellectis?
Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS LLE-DE-FRANCE I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]
MarketBeat Community Rating for Cellectis (CLLS)
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cellectis (NASDAQ:CLLS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Cellectis in the last 12 months. Their average twelve-month price target is $44.00, suggesting that the stock has a possible upside of 44.78%. The high price target for CLLS is $73.00 and the low price target for CLLS is $20.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.83 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $44.00 | $44.00 | $39.8333 | $39.8333 |
| Price Target Upside: | 44.78% upside | 25.36% upside | 39.13% upside | 19.80% upside |
Cellectis (NASDAQ:CLLS) Consensus Price Target History
Cellectis (NASDAQ:CLLS) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Cellectis (NASDAQ:CLLS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cellectis (NASDAQ CLLS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.41%
Institutional Ownership Percentage: 16.75%
Cellectis (NASDAQ CLLS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Cellectis (NASDAQ CLLS) News Headlines
| Source: |
|
Cellectis (NASDAQ:CLLS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cellectis (NASDAQ:CLLS) Income Statement, Balance Sheet and Cash Flow Statement
Cellectis (NASDAQ CLLS) Stock Chart for Thursday, May, 24, 2018
Loading chart…
